Redhill Biopharma Ltd ADR RDHL
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
Weekly Losses Deepen As Small Caps Lag And Yields Edge Higher Into Earnings Gauntlet
-
RedHill Biopharma Announces Operational Highlights and First Half 2026 Financial Results
-
RedHill Announces Transformational Acquisition of Commercialization Rights to Ferring’s Rebyota® and Clenpiq®
-
RedHill Announces Transformational Acquisition of Commercialization Rights to Ferring's Rebyota® and Clenpiq®
-
RedHill Divests Talicia® to Apotex for $18 Million Cash Upfront Plus Milestones to Fuel Strategic Growth Opportunities
-
Ebola Cases and Deaths Rapidly Mount - RedHill Updates on Opaganib Emergency Outbreak Development
Trading Information
- Previous Close Price
- $0.49
- Day Range
- $0.48–0.51
- 52-Week Range
- $0.44–2.14
- Bid/Ask
- $0.50 / $0.52
- Shares Outstanding
- 8.89M
- Market Cap
- $4.44M
- Volume/Avg
- 59,434 / 2M
Key Statistics
- Price/Earnings (Normalized)
- 4.68
- Price/Sales
- —
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- —
Company Profile
RedHill Biopharma Ltd is a specialty biopharmaceutical company mainly focused on the U.S. development and commercialization of drugs for GI diseases, infectious diseases, and oncology. The Company is mainly focused on the advancement of its development pipeline of clinical-stage therapeutic candidates and also commercializes its GI-related product, Talicia (omeprazole, amoxicillin, and rifabutin) in the U.S. Its therapeutic candidates include opaganib, RHB-204, RHB-104, RHB-102 (Bekinda), and RHB-107.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Stock Style Box
- Small Growth
- Total Number of Employees
- 23
- Website
- https://www.redhillbio.com
Valuation
|
Metric
|
RDHL
|
|---|---|
Price/Earnings (Normalized) | 4.68 |
Price/Book Value | — |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
RDHL
Financial Strength
|
Metric
|
RDHL
|
|---|---|
Quick Ratio | 0.34 |
Current Ratio | 0.34 |
Interest Coverage | −11.31 |
Quick Ratio
RDHL
Profitability
|
Metric
|
RDHL
|
|---|---|
Return on Assets (Normalized) | −35.75% |
Return on Equity (Normalized) | — |
Return on Invested Capital (Normalized) | −1,662.68% |
Return on Assets
RDHL
Drug Manufacturers - Specialty & Generic Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Merck KGaA ADR
MKKGY
| LOCK|z%%GPyr< | LOCK|@#!<Z | $70B | |||
| Teva Pharmaceutical Industries Ltd
TEVA
| LOCK|#sC^G&^H | LOCK|p#SR | $49B | |||
| Haleon PLC ADR
HLN
| LOCK|#SjBn>b | LOCK|$j | $44B | |||
| Zoetis Inc Class A
ZTS
| LOCK|g<Mf@<h@ | LOCK|w> | $32B | |||
| Viatris Inc
VTRS
| LOCK|jK^^JB | LOCK|SnS | $21B | |||
| Elanco Animal Health Inc
ELAN
| LOCK|qv | LOCK|%# | $12B | |||
| Dr Reddy's Laboratories Ltd ADR
RDY
| LOCK|#Qyvc^ | LOCK|tvh | $11B | |||
| Hims & Hers Health Inc Ordinary Shares - Class A
HIMS
| LOCK|llFhXV^ | LOCK|@D | $7B | |||
| Prestige Consumer Healthcare Inc
PBH
| LOCK|f&@jVhT | LOCK|%SbQ | $2B | |||
| Perrigo Co PLC
PRGO
| LOCK|^%$rl> | LOCK|$S@ | $2B |
United States